您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Epalrestat-d5
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Epalrestat-d5
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Epalrestat-d5图片
规格:98%
分子量:324.4
包装与价格:
包装价格(元)
500ug电议
1mg电议

产品介绍
A neuropeptide with diverse biological activities
货号:ajcx22428
CAS:N/A
分子式:C15H8D5NO3S2
分子量:324.4
溶解度:DMSO: slightly soluble,Methanol: slightly soluble
纯度:98%
存储:Store at -20°C
库存:现货

Background:

Epalrestat-d5is intended for use as an internal standard for the quantification of epalrestat by GC- or LC-MS. Epalrestat is an inhibitor of aldose reductase (IC50s = 0.01 and 0.26 µM for rat lens and human placenta aldose reductase, respectively).1It inhibits glucose-induced sorbitol accumulation in isolated rat lens, rat sciatic nerve, and human erythrocytes (IC50s = 1.5, 5, and 1.5 µM, respectively). It decreases high glucose-induced proliferation of vascular smooth muscle cells when used at a concentration of 10 nM and prevents high glucose-induced intracellular NADH/NAD+increases and membrane-bound PKC activation at 100 nM.2,3Epalrestat (20 and 40 mg/kg) improves motor nerve conduction velocity and decreases sorbitol content in the sciatic nerve and erythrocytes in a rat model of streptozotocin-induced diabetic neuropathy.4It also prevents capillary strand formation in a rat model of diabetes-induced retinal microangiopathy when administered at a dose of 50 mg/kg.5


1.Terashima, H., Hama, K., Yamamoto, R., et al.Effects of a new aldose reductase inhibitor on various tissues in vitroJ. Pharmacol. Exp. Ther.229(1)226-230(1984) 2.Yasunari, K., Kohno, M., Kano, H., et al.Aldose reductase inhibitor improves insulin-mediated glucose uptake and prevents migration of human coronary artery smooth muscle cells induced by high glucoseHypertension35(5)1092-1098(2000) 3.Yasunari, K., Kohno, M., Kano, H., et al.Aldose reductase inhibitor prevents hyperproliferation and hypertrophy of cultured rat vascular smooth muscle cells induced by high glucoseArterioscler. Thromb. Vasc. Biol.15(12)2207-2212(1995) 4.Kikkawa, R., Hatanaka, I., Yasuda, H., et al.Effect of a new aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2E)-methyl-3-phenylpropenylidene]rhodanine (ONO-2235) on peripheral nerve disorders in streptozotocin-diabetic ratsDiabetologia24(4)290-292(1983) 5.Kojima, K., Matsubara, H., Mizuno, K., et al.Experimentally induced diabetic retinal microangiopathy and polyol pathway. II. Effect of aldose reductase inhibitors on microangiopathyNippon Ganka Gakkai Zasshi89(2)247-256(1985)